These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 1674161)

  • 21. Prolactin stimulating effects of amoxapine and loxapine in psychiatric patients.
    Robertson AG; Berry R; Meltzer HY
    Psychopharmacology (Berl); 1982; 78(3):287-92. PubMed ID: 6818584
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Loxapine: a six-month evaluation in severely ill schizophrenic patients.
    Gallant DM; Bishop G; Steel CA; Bishop MP
    Curr Ther Res Clin Exp; 1973 Apr; 15(4):205-9. PubMed ID: 4633281
    [No Abstract]   [Full Text] [Related]  

  • 23. Low-dose zotepine in the maintenance treatment of schizophrenia.
    Fleischhacker WW; Stuppäck C; Barnas C; Unterweger B; Hinterhuber H
    Pharmacopsychiatry; 1987 Feb; 20(1 Spec No):61-3. PubMed ID: 2883685
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The relationship between negative symptoms of schizophrenia and extrapyramidal side effects with haloperidol and olanzapine.
    Allan ER; Sison CE; Alpert M; Connolly B; Crichton J
    Psychopharmacol Bull; 1998; 34(1):71-4. PubMed ID: 9564201
    [TBL] [Abstract][Full Text] [Related]  

  • 25. First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients.
    Popović I; Ravanić D; Popović V; Vladejić S; Stanojević A; Stojanović M
    Psychiatr Danub; 2011 Dec; 23(4):384-8. PubMed ID: 22075740
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects.
    Goff DC; Henderson DC; Amico E
    Am J Psychiatry; 1992 Sep; 149(9):1189-94. PubMed ID: 1503131
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia.
    Azorin JM; Spiegel R; Remington G; Vanelle JM; Péré JJ; Giguere M; Bourdeix I
    Am J Psychiatry; 2001 Aug; 158(8):1305-13. PubMed ID: 11481167
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and tolerability of a new antipsychotic compound (risperidone): results of a pilot study.
    Möller HJ; Pelzer E; Kissling W; Riehl T; Wernicke T
    Pharmacopsychiatry; 1991 Nov; 24(6):185-9. PubMed ID: 1725925
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Possible predictors of neuroleptic-resistant schizophrenic relapse: influence of negative symptoms and acute extrapyramidal side effects.
    Kinon BJ; Kane JM; Chakos M; Munne R
    Psychopharmacol Bull; 1993; 29(3):365-9. PubMed ID: 7907184
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gender differences in neuroleptic nonresponsive clozapine-treated schizophrenics.
    Szymanski S; Lieberman J; Pollack S; Kane JM; Safferman A; Munne R; Umbricht D; Woerner M; Masiar S; Kronig M
    Biol Psychiatry; 1996 Feb; 39(4):249-54. PubMed ID: 8645771
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diurnal variations of extrapyramidal symptoms induced by haloperidol in schizophrenic subjects.
    Torner C; Herrera-Estrella M; Gutiérrez JA; Aguilar-Roblero R
    Int J Neuropsychopharmacol; 2003 Sep; 6(3):243-6. PubMed ID: 12974990
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response.
    Breier AF; Malhotra AK; Su TP; Pinals DA; Elman I; Adler CM; Lafargue RT; Clifton A; Pickar D
    Am J Psychiatry; 1999 Feb; 156(2):294-8. PubMed ID: 9989566
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study.
    Bobes J; Arango C; Garcia-Garcia M; Rejas J;
    J Clin Psychiatry; 2010 Mar; 71(3):280-6. PubMed ID: 19895779
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of antipsychotic replacement with quetiapine on the symptoms and quality of life of schizophrenic patients with extrapyramidal symptoms.
    Taniguchi T; Sumitani S; Aono M; Iga J; Kinouchi S; Aki H; Matsushita M; Taniguchi K; Tsuno M; Yamanishi K; Tomotake M; Kaneda Y; Ohmori T
    Hum Psychopharmacol; 2006 Oct; 21(7):439-45. PubMed ID: 17029303
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Depressive syndromes in schizophrenic patients under neuroleptic therapy. ANI Study Group Berlin, Düsseldorf, Göttingen, Munich, Federal Republic of Germany.
    Bandelow B; Müller P; Frick U; Gaebel W; Linden M; Müller-Spahn F; Pietzcker A; Tegeler J
    Eur Arch Psychiatry Clin Neurosci; 1992; 241(5):291-5. PubMed ID: 1351405
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Depressive states occurring during the neuroleptic treatment of schizophrenia.
    Möller HJ; von Zerssen D
    Schizophr Bull; 1982; 8(1):109-17. PubMed ID: 6122264
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients.
    Nyberg S; Eriksson B; Oxenstierna G; Halldin C; Farde L
    Am J Psychiatry; 1999 Jun; 156(6):869-75. PubMed ID: 10360125
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BMY 14802, a sigma receptor ligand for the treatment of schizophrenia.
    Gewirtz GR; Gorman JM; Volavka J; Macaluso J; Gribkoff G; Taylor DP; Borison R
    Neuropsychopharmacology; 1994 Feb; 10(1):37-40. PubMed ID: 7910021
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: 26-week prospective study.
    Kwon JS; Jang JH; Kang DH; Yoo SY; Kim YK; Cho SJ;
    Psychiatry Clin Neurosci; 2009 Feb; 63(1):73-81. PubMed ID: 19154213
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Amisulpride versus haloperidol in treatment of schizophrenic patients--results of a double-blind study.
    Delcker A; Schoon ML; Oczkowski B; Gaertner HJ
    Pharmacopsychiatry; 1990 May; 23(3):125-30. PubMed ID: 1973843
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.